Daewoong Pharmaceutical has strengthened its position in the market by surpassing 1 trillion won in external prescriptions for the second consecutive year. External prescriptions refer to the prescription amount of medicines that patients receive after being treated at a hospital or clinic, which are then dispensed at pharmacies or other external locations.
Daewoong Pharmaceutical noted on the 12th that according to Ubiest data, last year's external prescriptions amounted to 1.0332 trillion won. The company explained that the development of innovative new drugs and co-promotion strategies were key growth factors.
Among its main products, the external prescription amount for the gastroesophageal reflux disease treatment agent Pexuclu increased by 47% year-over-year to 78.8 billion won, while the diabetes treatment agent Enblo recorded a 261% increase to 12.3 billion won. Co-promotion items with partner companies are also showing stable growth. The external prescription amounts for the anticoagulant Lixiana, co-promoted with Daiichi Sankyo, and the antihypertensive drug Sevican (Sevican, Sevican HCT) increased by 12% and 4% year-over-year, recording 117.5 billion won and 110.9 billion won, respectively. The external prescription amount for the diabetes medication Gemiglo series (Gemiglo, Gemidapa, Gemimet) co-promoted with LG CHEM increased by 6% year-over-year to 152.5 billion won.
The company explained that the 'four-stage validation strategy' applied in marketing has also been effective. The four-stage validation strategy involves organizing messages through deep learning, verification through consultations with internal and external experts, on-site verification with customers, and applying the marketing and sales strategies. Additionally, the digital healthcare device business, seen as a future growth driver, has begun contributing to the expansion of prescription market performance.
Previously, Daewoong Pharmaceutical introduced continuous glucose monitoring devices 'FreeStyle Libre', wearable electrocardiogram devices 'Mobicare', ring-type continuous blood pressure monitors 'CartBP', and AI diagnostic support solutions for retinal diseases 'Whiskey'. Mobicare achieved a 1st market share in the domestic wearable electrocardiogram market and is used in over 840 hospitals nationwide. CartBP has been adopted by over 1,200 hospitals within just four months of its release.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "The fact that Daewoong Pharmaceutical recorded 1 trillion won in external prescriptions for the second consecutive year is thanks to not only new drug development but also to our differentiated market approach through the 'four-stage validation' strategy. We will strengthen research and development to continue our sustainable growth and lead innovation in the healthcare industry through new drugs, digital healthcare, and global market expansion."